G1 Therapeutics Stock Z Score
| GTHX Stock | USD 3.99 0.20 4.77% |
GTHX | Z Score |
G1 Therapeutics Company Z Score Analysis
G1 Therapeutics' Z-Score is a simple linear, multi-factor model that measures the financial health and economic stability of a company. The score is used to predict the probability of a firm going into bankruptcy within next 24 months or two fiscal years from the day stated on the accounting statements used to calculate it. The model uses five fundamental business ratios that are weighted according to algorithm of Professor Edward Altman who developed it in the late 1960s at New York University..
| |||||||
| |||||||
| |||||||
| |||||||
|
GTHX Z Score Driver Correlations
Understanding the fundamental principles of building solid financial models for G1 Therapeutics is extremely important. It helps to project a fair market value of GTHX Stock properly, considering its historical fundamentals such as Z Score. Since G1 Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of G1 Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of G1 Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
To calculate a Z-Score, one would need to know a company's current working capital, its total assets and liabilities, and the amount of its latest earnings as well as earnings before interest and tax. Z-Scores can be used to compare the odds of bankruptcy of companies in a similar line of business or firms operating in the same industry. Companies with Z-Scores above 3.1 are generally considered to be stable and healthy with a low probability of bankruptcy. Scores that fall between 1.8 and 3.1 lie in a so-called 'grey area,' with scores of less than 1 indicating the highest probability of distress. Z Score is a used widely measure by financial auditors, accountants, money managers, loan processors, wealth advisers, and day traders. In the last 25 years, many financial models that utilize z-scores proved it to be successful as a predictor of corporate bankruptcy.
| Competition |
According to the company's disclosures, G1 Therapeutics has a Z Score of 0.0. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The z score for all United States stocks is 100.0% higher than that of the company.
G1 Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of G1 Therapeutics from analyzing G1 Therapeutics' financial statements. These drivers represent accounts that assess G1 Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of G1 Therapeutics' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 991.1M | 681.4M | 428.2M | 236.9M | 157.8M | 149.9M | |
| Enterprise Value | 732.1M | 501.9M | 290.1M | 226.1M | 182.7M | 173.5M |
G1 Therapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in G1 Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of G1 Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing G1 Therapeutics' value.| Shares | Bank Of America Corp | 2023-12-31 | 279.5 K | Simplex Trading, Llc | 2023-12-31 | 233.6 K | Connor Clark & Lunn Inv Mgmt Ltd | 2023-12-31 | 192.1 K | Needham Investment Management, Llc | 2023-12-31 | 180 K | Level Four Advisory Services, Llc | 2023-12-31 | 178.6 K | Morgan Stanley - Brokerage Accounts | 2023-12-31 | 170.1 K | Two Sigma Investments Llc | 2023-12-31 | 162.1 K | State Street Corporation | 2023-12-31 | 161.1 K | Xtx Topco Ltd | 2023-12-31 | 157.2 K | Vanguard Group Inc | 2023-12-31 | 2 M | Susquehanna International Group, Llp | 2023-12-31 | 1.6 M |
GTHX Fundamentals
| Return On Equity | -0.92 | ||||
| Return On Asset | -0.16 | ||||
| Profit Margin | (0.58) % | ||||
| Operating Margin | (0.60) % | ||||
| Current Valuation | 193.73 M | ||||
| Shares Outstanding | 52.2 M | ||||
| Shares Owned By Insiders | 11.68 % | ||||
| Shares Owned By Institutions | 30.56 % | ||||
| Number Of Shares Shorted | 2.76 M | ||||
| Price To Earning | (1.95) X | ||||
| Price To Book | 6.71 X | ||||
| Price To Sales | 2.88 X | ||||
| Revenue | 82.51 M | ||||
| Gross Profit | 47.55 M | ||||
| EBITDA | (39.01 M) | ||||
| Net Income | (47.97 M) | ||||
| Cash And Equivalents | 143.96 M | ||||
| Cash Per Share | 3.37 X | ||||
| Total Debt | 57.17 M | ||||
| Debt To Equity | 1.24 % | ||||
| Current Ratio | 4.75 X | ||||
| Book Value Per Share | 0.68 X | ||||
| Cash Flow From Operations | (38.34 M) | ||||
| Short Ratio | 2.51 X | ||||
| Earnings Per Share | (0.93) X | ||||
| Target Price | 8.5 | ||||
| Number Of Employees | 100 | ||||
| Beta | 1.7 | ||||
| Market Capitalization | 219.5 M | ||||
| Total Asset | 121.54 M | ||||
| Retained Earnings | (779.99 M) | ||||
| Working Capital | 85.23 M | ||||
| Current Asset | 252.33 M | ||||
| Current Liabilities | 9.86 M | ||||
| Net Asset | 121.54 M |
About G1 Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze G1 Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of G1 Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of G1 Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards G1 Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, G1 Therapeutics' short interest history, or implied volatility extrapolated from G1 Therapeutics options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out G1 Therapeutics Piotroski F Score and G1 Therapeutics Valuation analysis. For more information on how to buy GTHX Stock please use our How to Invest in G1 Therapeutics guide.Note that the G1 Therapeutics information on this page should be used as a complementary analysis to other G1 Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.
Complementary Tools for GTHX Stock analysis
When running G1 Therapeutics' price analysis, check to measure G1 Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy G1 Therapeutics is operating at the current time. Most of G1 Therapeutics' value examination focuses on studying past and present price action to predict the probability of G1 Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move G1 Therapeutics' price. Additionally, you may evaluate how the addition of G1 Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Stocks Directory Find actively traded stocks across global markets | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios |
Is G1 Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of G1 Therapeutics. If investors know GTHX will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about G1 Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.93) | Revenue Per Share 1.595 | Quarterly Revenue Growth 0.451 | Return On Assets (0.16) | Return On Equity (0.92) |
The market value of G1 Therapeutics is measured differently than its book value, which is the value of GTHX that is recorded on the company's balance sheet. Investors also form their own opinion of G1 Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is G1 Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because G1 Therapeutics' market value can be influenced by many factors that don't directly affect G1 Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between G1 Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if G1 Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, G1 Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.